1. Overview of the 4UP Strategy (Announced March 24, 2026)
On March 24, 2026, the Ministry of Health and Welfare (MOHW) and the Ministry of SMEs and Startups (MSS) jointly announced the '4UP Strategy' to nurture pharma-bio ventures. The initiative aims to build an integrated government support system for creating K-blockbuster new drugs.
Four Pillars of the 4UP Framework
Scale-Up: Foster mid-sized bio companies with annual revenue exceeding KRW 10 billion, targeting 50 firms over 5 yearsSpeed-Up: Reduce commercialization timelines by 30% through intensive support during clinical trials and approval phasesLevel-Up: Customized R&D support by Technology Readiness Level (TRL), with collaboration between KHIDI and SBCSynergy-Up: Eliminate inter-ministry silos and build an integrated platformAs a new collaborative program between MOHW and MSS, an annual budget of approximately KRW 420 billion has been allocated, with the core objective of bridging stage-specific support gaps for K-blockbuster drug creation.
2. Stage-Specific Gap-Bridging Strategies
Startup/Early Stage: K-Startup·KHIDI Integrated Application System
Previously, early-stage bio ventures had to apply separately to K-Startup (MSS) and KHIDI (MOHW) programs. Starting June 2026, an integrated application system will go live, allowing simultaneous submission to both ministries with shared evaluation materials.
Eligibility: Bio ventures within 3 years of founding (seed to pre-Series A)Funding: Up to KRW 500 million per company (split across 2 years)Accelerated review: Reduced from 4 months to 2 monthsGrowth Stage: AI-Driven Venture-Pharma Joint R&D
A new program will match mid-sized pharmaceutical companies with AI-based bio ventures for joint R&D.
Matching scale: 30 consortia selected annuallyFunding: Up to KRW 2 billion per consortium over 3 yearsFocus areas: AI drug discovery, digital therapeutics, bio data analyticsPrivate matching: Pharmaceutical companies must match 50% or moreGlobalization: 'K-Bio Tech Commercialization Running Together'
An integrated package for global expansion, supporting technology transfer, overseas clinical trials, and local subsidiary establishment.
Global licensing negotiation advisory (KOTRA·KHIDI collaboration)Up to KRW 300 million for FDA·EMA approval consultingSubsidized residency at Boston and San Diego global hubs3. Use-Case Scenarios for SME Bio Companies
AI Joint R&D Matching Application Process
Preparation: Document AI capabilities and clinical data assetsRegistration: Register company profile on the KHIDI matching platformPharma engagement: 1:1 meetings with interested pharmaceutical companies (4 government-hosted matching events per year)Joint proposal drafting: Include technical validation and market analysisEvaluation: 60% technical merit, 40% commercial viabilityIntegrated Application System: Key Tips
Document unification: Submit business registration, financials, and technical materials only onceCross-evaluation safeguards: Pre-check for duplicate funding eligibilityConsulting essential: Pre-diagnose which ministry's program best fits your stageConnecting to Commercialization Infrastructure
GMP facilities: Priority access to Osong and Daegu-Gyeongbuk Advanced Medical ComplexesPreclinical CRO: Korea Institute of Toxicology (KIT) vouchers up to KRW 50 millionClinical CRO: Free consulting from KoNECT (National Clinical Trial Support Foundation)4. KITIM Consulting Services
KITIM offers the following consulting to help pharma-bio ventures effectively leverage the 4UP Strategy.
4UP Stage-Specific Program Matching: Diagnose your growth stage and recommend optimal programsBusiness Plan & Tech Commercialization Strategy: Specialized templates for AI joint R&D and global expansion programsGovernment R&D Project Planning Advisory: TRL-based R&D roadmap design and evaluation response strategiesIntegrated Cross-Ministry Application Support: Streamlined materials for simultaneous MOHW·MSS submissionsWith the 4UP Strategy launching in earnest in 2026, swift action will define competitiveness. Partner with KITIM's expert consultants to prepare your pharma-bio venture's next leap forward. Request a free corporate diagnosis to receive tailored 4UP program and matching strategy recommendations for your company.
